Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.

Abstract

PURPOSE To evaluate the effects of intravitreal bevacizumab and ranibizumab treatments in retinal angiomatous proliferation (RAP). METHODS Fifty patients affected by RAP were randomly assigned either to intravitreal bevacizumab injection (IVBI) or intravitreal ranibizumab injection (IVRI). After a loading phase including three consecutive monthly… (More)
DOI: 10.1111/j.1755-3768.2011.02265.x

Topics

Cite this paper

@article{Parodi2013IntravitrealBV, title={Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.}, author={M. Parodi and Pierluigi Iacono and Francesca Menchini and Saumil Sheth and Giovanni Polini and Raffaele Pittino and Francesco Bandello}, journal={Acta ophthalmologica}, year={2013}, volume={91 3}, pages={267-73} }